UPDATE: Sequenom Upgraded to Outperform at Wedbush after Overblown Fears from WSJ Article

In a report published by Wedbush Securities, analyst Zarak Khurshid upgraded Sequenom (NASDAQ: SQNM ) from Neutral to Outperform and maintained a $5 price target. In the report, Wedbush noted, "We suspect that yesterday's ~5% selloff was partially due to a leaked WSJ article, which included comments from the FDA